16:11 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Ahead of ESMO data, Clovis' Rubraca dubbed a breakthrough for prostate cancer

Clovis Oncology Inc. (NASDAQ:CLVS) gained $2.25 to $31.39 on Oct. 2 after it said FDA granted breakthrough therapy designation for Rubraca rucaparib to treat metastatic castration resistant prostate cancer. The designation was based on initial...
19:01 , Oct 2, 2018 |  BC Extra  |  Company News

Ahead of ESMO data, Clovis' Rubraca dubbed a breakthrough for prostate cancer

Clovis Oncology Inc. (NASDAQ:CLVS) gained $2.25 to $31.39 on Tuesday after it said FDA granted breakthrough therapy designation for Rubraca rucaparib to treat metastatic castration resistant prostate cancer. The designation was based on initial data...
21:45 , Oct 1, 2018 |  BC Extra  |  Company News

Pfizer COO Bourla to succeed Read as CEO

Pfizer Inc. (NYSE:PFE) named an insider, COO Albert Bourla, to succeed Ian Read as CEO on Jan. 1. During Read’s eight-year tenure, he reshaped Pfizer into a slimmer, three-part organization and helped it navigate key...
18:19 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Arvinas raises $120M in IPO

Arvinas Inc. (NASDAQ:ARVN) raised $120 million late Sept. 26 through the sale of 7.5 million shares at $16 in its bumped-up IPO. The price, at the top of its proposed $14-$16 range, values the company...
17:20 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

GTx's enobosarm fails Phase II for stress urinary incontinence

GTx Inc. (NASDAQ:GTXI) said it enobosarm (GTx-024) failed in the Phase II ASTRID trial to treat stress urinary incontinence. Among the 493 postmenopausal women enrolled in the double-blind, U.S. trial, neither of two doses of...
15:34 , Sep 27, 2018 |  BC Extra  |  Financial News

Trio of IPOs price: Arvinas, Sutro, Urovant

Arvinas Inc. (NASDAQ:ARVN), Sutro Biopharma Inc. (NASDAQ:STRO) and Urovant Sciences Ltd. (NASDAQ:UROV) each priced IPOs late Wednesday, raising a total of $345 million. On Thursday, Arvinas gained $0.05 to $16, and Sutro was up $0.20 to...
17:35 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample and mouse studies suggest inhibiting glutamine uptake in cancer-associated prostate fibroblasts could help treat prostate cancers resistant to androgen receptor antagonists. In prostate cancer patients, high plasma levels of glutamine...
22:15 , Sep 21, 2018 |  BC Extra  |  Clinical News

GTx shares crater after incontinence readout

GTx Inc. (NASDAQ:GTXI) shed 92% of its value Friday, falling from the small cap band to trading at roughly the value of its cash, after the company's enobosarm (GTx-024) failed in the Phase II ASTRID...
19:37 , Sep 20, 2018 |  BC Innovations  |  Emerging Company Profile

Recalcitrant Targets

With a fresh take on small molecule microarray technology, Kronos Bio Inc. aims to identify small molecule inhibitors of oncology targets considered undruggable, starting with a splice variant of the androgen receptor expressed in metastatic...
22:42 , Sep 13, 2018 |  BC Week In Review  |  Company News

Endocyte raises $175M

Endocyte Inc. (NASDAQ:ECYT) raised $175 million through the sale of 9.5 million shares at $18.50 in a follow-on underwritten by Jefferies, Wells Fargo, RBC Capital Markets and Wedbush. The price was a 2% discount to...